artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography

AI-CAD marked axillary lymph node and region in right upper outer quadrant (arrows and thin line outlining both sites) and assigned an abnormality score of 28%.


August 11, 2021 — According to an open-access Editor’s Choice article in the American Journal of Roentgenology (AJR), artificial intelligence-based computer-aided detection (AI-CAD) can be a practical addition for lowering false-positive findings when performing post-breast conserving therapy (BCT) surveillance mammography.

“After BCT, adjunct digital breast tomosynthesis (DBT) or AI-CAD reduced recall rates and improved accuracy in the ipsilateral and contralateral breasts compared with digital mammography (DM),” wrote lead investigator Jung Hyun Yoon. “In the ipsilateral breast, addition of AI-CAD resulted in lower recall rate and higher accuracy than addition of DBT.”

Yoon and colleagues’ single-center retrospective study included 314 women (mean age, 53.2 years; 4 with bilateral breast cancer) who underwent BCT followed by DBT (mean interval from surgery to DBT, 15.2 months). Three breast radiologists independently reviewed images in three sessions: DM, DM with DBT, and DM with AI-CAD. Recall rates and diagnostic performance were compared between these three sessions using readers’ mean results.

Among these 314 women, the mean ipsilateral breast recall rate among all three readers was lower (p<.001) for DM with AI-CAD (1.9%) than for DM with DBT (4.1%). In the ipsilateral breast, both mean accuracy (97.0% vs 94.8%, p=.02) and specificity (98.3% vs 96.1%, p=.003) were higher for DM with AI-CAD than for DM with DBT, respectively.

Acknowledging that data regarding other AI-CAD applications for the post-BCT breast are scarce, “our study shows that recall rates decrease significantly when DBT or AI-CAD are used as adjuncts to DM for surveillance of the ipsilateral and contralateral breasts in women with a personal history of breast cancer after BCT,” the authors of this AJR article concluded.

For more information: www.arrs.org


Related Content

News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Artificial Intelligence

February 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered solutions that enable medical providers ...

Time February 28, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
Feature | HIMSS | Christine Book

February 26, 2024 — This year’s Healthcare Information and Management Systems Society HIMSS Global Conference and ...

Time February 23, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
Feature | HIMSS | By Christine Book

February 22, 2024 — With just weeks to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Time February 22, 2024
arrow
News | Artificial Intelligence

February 22, 2024 — Hartford HealthCare has announced the unveiling of its Center for AI Innovation in Healthcare ...

Time February 21, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time February 21, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
Subscribe Now